Financial resources required for tuberculosis control to achieve global targets set for 2015

Abstract

Objective To estimate the financial resources required to achieve the 2015 targets for global tuberculosis (TB) control, which have been set within the framework of the Millennium Development Goals (MDGs). Methods The Global Plan to Stop TB, 2006-2015 was developed by the Stop TB Partnership. It sets out what needs to be done to achieve the 2015 targets for global TB control, based on WHO's Stop TB Strategy. Plan costs were estimated using spreadsheet models that included epidemiological, demographic, planning and unit cost data. Findings A total of US$ 56 billion is required during the period 2006-2015 (93% for TB-endemic countries, 7% for international technical agencies), increasing from US$ 3.5 billion in 2006 to US$ 6.7 billion in 2015. The single biggest cost (US$ 3 billion per year) is for the treatment of drug-susceptible cases in DOTS programmes. Other major costs are treatment of patients with multiand extensively drug-resistant TB (MDR-TB and XDR-TB), collaborative TB/HIV activities, and advocacy, communication and social mobilization. Low-income countries account for 41% of total funding needs and 65% of funding needs for TB/HIV. Middle-income countries account for 72% of the funding needed for treatment of MDR-TB and XDR-TB. African countries require the largest increases in funding. Conclusion Achieving the 2015 global targets set for TB control requires a major increase in funding. To support resource mobilization, comprehensive and costed national plans that are in line with the Global Plan to Stop TB are needed, backed up by robust assessments of the funding that can be raised in each country from domestic sources and the balance that is needed from donors.Bulletin of the World Health Organization 2008;86:568-576.Une traduction en français de ce résumé figure à la fin de l'article. Al final del artículo se facilita una traducción al español. ‫املقالة.‬ ‫لهذه‬ ‫الكامل‬ ‫النص‬ ‫نهاية‬ ‫يف‬ ‫الخالصة‬ ‫لهذه‬ ‫العربية‬ ‫الرتجمة‬

Tuberculosis screening in high human immunodeficiency virus prevalence settings: turning promise into reality [State of the art series. Active case finding/screening. Number 5 in the series]

“…Even relatively small per-patient costs will require substantial additional funding to be affordable by national TB control programmes in low-income countries. 98 Effective targeting to high TB prevalence risk groups and populations will be critical for maximising cost-effectiveness. 44 …”

Isolated Pancreatic Tuberculosis Mimicking Pancreatic Cancer: A Diagnostic Challenge

“…Tuberculosis is a common occurrence in certain endemic zones of Asia and Africa [7]. Even though, tuberculosis primarily affects the lungs, isolated abdominal tuberculosis is not rare with incidence ranging from 0.59% to 12% [1, 8].…”

Disease appearance and evolution against a background of climate change and reduced resources

“…Collapse of public-health systems, lack of national programmes for case detection and treatment, poor laboratory support for drug susceptibility testing and little political commitment have all been thought to contribute to the emergence and spread of MDR/XDR TB. This led to the Stop TB partnership being founded with the WHO in 2000, whose goal is to reduce the burden of TB by 2015 in line with the millennium development goals, through several key objectives [22]. Along with expansion of high-quality detection and treatment of TB cases, there are also separate objectives regarding management of MDR TB plus TB/HIV collaborations, and several other interventions including health-system strengthening and addressing the needs of poor and vulnerable populations [23].…”